Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress [Yahoo! Finance]
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: Yahoo! Finance
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focusing on the development of novel oral therapies for autoimmune and inflammatory disorders, aiming to transition treatments from injectable to oral formats. In its latest earnings report for the third quarter of 2024, Ventyx Biosciences shared financial results and updates on its pipeline progress. The company highlighted upcoming clinical trials and expected results, maintaining a strong cash position to fund operations through at least the second half of 2026. Key financial metrics included a cash balance of $274.8 million as of September 30, 2024, and a net loss of $35.2 million for the quarter, which improved from a net loss of $54.0 million in the same period last year. Ventyx is advancing several clinical trials, including a Phase 2 trial for VTX3232 in obesity and cardiometabolic risk factors, and another for VTX2735 in recurrent pericarditis, both expected to initiate
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]Yahoo! Finance
- Ventyx Biosciences to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock, down previously from $10.00.MarketBeat
- Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire
VTYX
Earnings
- 8/8/24 - Beat
VTYX
Sec Filings
- 11/18/24 - Form EFFECT
- 11/15/24 - Form 424B3
- 11/14/24 - Form SC
- VTYX's page on the SEC website